Despite an initial response to targeted therapies, most NSCLC with EGFR-TKI sensitizing mutations relapsed after 8–16 months of treatment due to the emergence of acquired drug resistance mechanisms12. This evidence concerns the gene EGFR and non-small cell lung carcinoma.